摘要
目的研讨老年卒中后抑郁患者运用艾司西酞普兰与文拉法辛缓释剂治疗的临床价值。方法依据随机非盲法将80例符合标准的老年卒中后抑郁患者归人两组（各40例）试验，Ⅰ组接受文拉法辛缓释剂治疗，Ⅱ组接受艾司西酞普兰治疗，对比评估两组治疗前后的HAMD评测结果及不良反应发生情况。结果治疗前与治疗后第4、8周末，两组接受HAMD量表评测，结果相比差异无统计学意义（P〉0．05），但治疗后第1、2周末，Ⅱ组的HAMD评测值相比Ⅰ组显著降低，两组比较差异有统计学意义（P〈0．05）。两组观察期间均有产生不良反应，且Ⅱ组总发生率相对Ⅰ组低，两组比较差异有统计学意义（P〈0．05）。结论艾司西酞普兰、文拉法辛缓释剂均有确切的抗抑郁效果，但前者起效较快、安全性较高，更适合作为临床治疗老年卒中后抑郁的推荐药物。
Objective To study the clinical values of escitalopram and venlafaxine sustained-release agents for elderly patients with post-stroke depression. Methods 80 elderly patients with post-stroke depression were divided into group Ⅰ and group Ⅱ by randomized non-blind method. Group I were treated with venlafaxine sustained-release agents and group Ⅱ with escitalopram. The results of HAMD evaluation and the occurrence of adverse reactions were evaluated before and after the treatment. Results There were no statistical differences in the HAMD scores between the two groups before and 4 and 8 weeks after the treatment （all P〉 0.05）. 1 and 2 weeks after the treatment, the HAMD scores were significant lower in group Ⅱ than in group Ⅰ , with statitical differences （all P 〈0.05）. The incidence of adverse reactions was lower in group Ⅱ than in group Ⅰ （P〈0.05）. Conclusion Escitalopram and venlafaxine sustained-release agents both have antidepressant effect, but the former has quicker effect and is safer, so it is more suitable as a recommended drug for the treatment of poststroke depression in the elderly.
出处
《国际医药卫生导报》
2017年第21期3397-3399,共3页
International Medicine and Health Guidance News
关键词
卒中
抑郁
艾司西酞普兰
文拉法辛缓释剂
临床价值
Stroke
Depression
Escitalopram
Venlafaxine sustained release agents
Clinical value
